Poland· PL-100518770
Leqembi
A lecanemab product containing lecanemabum, registered in Poland by Eisai GmbH. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lecanemab is registered in 10 of 19 countries.
Countries holding a registration under ATC N06DX04 (lecanemab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Lecanemab · ATC N06DX04
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Lecanemabum
- Manufacturer
- Eisai GmbH
- Country
- Poland (PL)
- ATC code
- N06DX04
- ATC class
- Lecanemab
- Defined daily dose
- 50 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin03400955105862
- gtin03400955105879
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lecanemab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumLeqembi 100 mg/mlEisai
- CzechiaLEQEMBIEisai GmbH, Frankfurt am Main
- FinlandLEQEMBIEisai GmbH
- IrelandLEQEMBI 100 mg/mL concentrate for solution for infusionEisai GmbH
- IcelandLeqembiEisai GmbH
- SwedenLEQEMBI 100 mg/ml Koncentrat till infusionsvätska, lösningEisai GmbH
- United StatesLECANEMAB AUTOINJECTOREisai Inc.
- United KingdomLeqembi 200mg/2ml concentrate for solution for infusion vialsEisai Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Leqembi
- Liechtenstein · Leqembi
- Norway · Leqembi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a75461cb-9d33-471c-a1de-0562567a2a99 GET /v1/drugs/a75461cb-9d33-471c-a1de-0562567a2a99?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "100 mg/ml",
"packaging": "Rpz ¦ EU/1/24/1891/001 ¦ 162119\n1 fiol. 2 ml\n¦ UR/Z/4c/138/26 - 03400955105862\nRpz ¦ EU/1/24/1891/002 ¦ 162120\n1 fiol. 5 ml\n¦ UR/Z/4c/139/26 - 03400955105879",
"substance": "Lecanemabum 100 mg/ml",
"common_name": "Lecanemabum",
"pl_product_id": "100518770",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about lecanemab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.